TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Immuron Limited ( (AU:IMC) ) is now available.
Immuron Limited announced a change in the director’s interest, with Paul Brennan acquiring 1,000,000 unlisted options, increasing his direct holdings to 2,000,000 options. This change was approved by shareholders during the company’s Annual General Meeting, potentially strengthening the alignment of the director’s interests with the company’s strategic goals.
More about Immuron Limited
Immuron Limited is a biopharmaceutical company focused on developing and commercializing oral immunotherapy products for the treatment of gut-mediated diseases. The company primarily targets the healthcare sector with its innovative solutions aimed at addressing gastrointestinal health issues.
Average Trading Volume: 538,302
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$17.23M
See more data about IMC stock on TipRanks’ Stock Analysis page.